Binod Dhakal, MD, MS, and a panel of experts in multiple myeloma provide a look at an upcoming Cancer Network Training Academy program discussing how to incorporate bispecific antibodies in the treatment of multiple myeloma, and how healthcare systems implement step-up dosing, treatment doses and transition of care. The panel also offers insights into the recommended strategies for monitoring patients receiving treatment with bispecifics.
EP. 1: Overview of Treatment Options for the Management of Relapsed/Refractory Multiple Myeloma (R/R MM)May 31st 2023
Binod Dhakal, MD, MS, discusses the management of relapsed multiple myeloma and the various treatment options available.
EP. 2: Data Updates on BCMA-Targeting Bispecific Antibodies in R/R MM TreatmentMay 31st 2023
Dr Cindy Varga discusses recent data on the FDA-approved agent teclistamab, a bispecific antibody for patients with relapsed/refractory multiple myeloma.